Pandorum Tech in pact with Bharat Biotech’s Nucelion for exosome-based therapeutics

HYDERABAD: Bengaluru-based clinical-stage regenerative medicine player Pandorum Technologies has entered into a strategic collaboration with Bharat Biotech’s contract research, development and manufacturing organisation (CRDMO) arm, Nucelion Therapeutics, to expand the manufacturing capabilities for its exosome-based therapeutic platform across the Asia-Pacific (APAC) region.Pandorum plans to leverage Nucelion Therapeutics’ manufacturing capabilities to support its regional supply and regulatory readiness. The partnership will boost India’s growing capability to develop and manufacture cutting-edge biologic therapies for the world, they said on Tuesday.While Pandorum’s current programmes will cater to those suffering from ocular surface injury and inflammatory corneal diseases, including Stevens–Johnson syndrome (SJS), Neurotrophic Keratitis, it plans to expand its disease-modifying treatments to reverse degenerative changes of skin, pulmonary, and other organ systems that are affected by inflammation, vascular pathologies and fibrosis.Dr Jitendra Kumar, managing director, BIRAC, Dept of Biotechnology, govt of India, said the strategic collaboration to manufacture advanced therapeutics will send an important signal about the readiness of both Innovate and Make in India to address unmet global clinical needs.Nucelion Therapeutics CBO Dr Raghu Malapaka said their advanced manufacturing platforms and quality systems, which are designed to support complex biologics, will enable scalable production of Pandorum’s designer exosome-based assets, including Kuragenx, which has the potential to redefine the treatment paradigm for ocular diseases, for patients across APAC.“Pandorum is building a global regenerative medicine platform designed for scale, consistency, and partnership. As our programmes advance toward clinical and commercial milestones, establishing robust, regionally aligned manufacturing infrastructure is a strategic priority,” said Dr Tuhin Bhowmick, co-founder and CEO, Pandorum Technologies.“Nucelion Therapeutics brings strong expertise in advanced biologics manufacturing and a high-quality operational environment that aligns well with our long-term vision of delivering programmable exosome therapies to patients worldwide,” he added.